COSCIENS Biopharma Inc T.AEZS

PGX-YBG

[prophetoffactz]

Based on average timeline from submission to the journal Biomaterials to publishing the comprehensive article on PGX-YBG/Fibrosis could be published within the next 30 days. In the October Small Cap Discoveries presentation Gilles said a short 6 month toxicology study was required for the go/no go decision. It has now been about 10 months since the Small Cap Discoveries presentation. Will wee soon see a comprehensive peer-reviewed article in a leading scientific journal, toxicology results, and a 'go' clinical trial decision for this program? Avalyn Pharma raised C$80 million going into its Phase I clinical trial. That was before COVID fibrosis. Avalyn's program was assisted by the same McMaster scientists that have worked on CSCI's program(Dr. Kolb, Dr. Ask). Dr. Kolb previously said that if preclinical results are replicated in humans this program it "...could profoundly change the landscape of fibrotic lung disease therapeutics..." Dr. Ask said it could also address fibrosis outside the lungs. PGX-YBG could also be used an an inhaled delivery system for other drugs. PGX-YBG has also been studied preclinically with another drug already used to treat COVID patients.

With the merger completed CZO now has the resources and capabilities to move a program into the clinic. PGX-YBG is also expected to reach the decision point for mass industrialization this quarter(100L commissioning). AEZS also already has a diagnostic product that has been approved by the FDA and Europrean authorities.

CZO's Nov. 2023 news release:

"Yeast Beta Glucan (YBG) - Potential Inhalo-Therapeutic

• Following the announcement of encouraging results made at two major international conferences earlier this year demonstrating that PGX-YBG is respirable and able to safely and reliably reprogram macrophages in the lungs in pre-clinical mouse models, additional research at McMaster University clearly showed that PGX-YBG gets into the macrophage cell. This important finding further supports the potential of YBG to act as a stand-alone and/or a carrier for other bioactives when transported by macrophages cells."

April 2024 news release:

• "Announced on May 23, 2023 the completion of CHRP collaboration with McMaster University with encouraging results evaluating PGX-processed YBG for interstitial lung diseases. These results triggered presentations at International scientific conferences confirming that PGX-YBG is suitable for inhalation and can act through a newly discovered mechanism of action through specific binding on white blood cells (macrophages) involved in the inflammation and fibrotic process. A comprehensive scientific article was recently submitted to the Biomaterials scientific journal."